February 18, 2015 @ 2:00 pm
Yale Club
50 Vanderbilt Avenue
New York, NY 10017

You are invited to come and meet the senior management team and hear the clinical strategy being pursued over 2015-16.

Novogen is a public (ASX; NASDAQ) Australian-US drug development company bringing a generational change in cytotoxic cancer chemotherapy.
Dr Graham Kelly, Novogen Group CEO and Executive Chairman, will present an overview of the clinical and corporate strategies for the Novogen Group for 2015-2016.

Professor Gil Mor PhD MD of Yale Medical School will present a talk entitled ‘Cantrixil: A Novel Therapy to Target Cancer Stem Cells to Prevent Tumor Recurrence.”

Dr Marc Symons PhD of the Feinstein Institute for Medical Research at North Shore-LIJ will present a talk entitled “Development of TRXE-009 for the Treatment of Brain Cancer.”

Dr Andrew Heaton, Novogen VP Drug Design and Manufacturing, and Mr Robert Kennedy, Novogen VP Corporate Relations (US), also will be in attendance.

People interested in attending will need to confirm by contacting prue.kelly@novogen.com